Gentiopicroside may therefore have novel value as a therapeutic agent that can treat RA via inhibiting this ROS-NF-κB-NLRP3 inflammasome axis, although further clinical trials will be needed to validate this possibility. Here, NLRP3 is linked to rheumatoid arthritis.